Trial Profile
A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms BioPATH
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 24 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 14 Dec 2012 Planned End Date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.